Study of a new under-the-skin multiple sclerosis treatment
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new way to give ocrelizumab, an approved MS treatment, as a shot under the skin instead of through an IV. It aims to see if it's safe and works well for people with relapsing or primary progressive MS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of relapsing or primary progressive multiple sclerosis.
- Your disability level must be mild to moderate (EDSS score between 0 and 6.5).
- No major infections in the past 8 weeks, and no active infections now.
- No history of certain brain infections (PML) or cancer in the last 10 years.
- No prior treatment with certain MS drugs like fingolimod or alemtuzumab in the last 6 weeks or ever, depending on the drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This study compares a new drug called PB018 with the approved MS drug Ocrevus. Researchers want to see if PB018 works similarly and is safe for people with relapsing or progressive forms of MS.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.